CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells

Journal of Immunotherapy

Volumn 25, Issue 6, 2002, Pages 455-468

  Hsu, Frank J ^a   Komarovskaya, Marina ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

Anti CD20; Cross presentation; Dendritic cell; Idiotype; Vaccine

Indexed keywords

ANTIBODY; CD20 ANTIBODY; CD20 ANTIGEN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; IMMUNOGLOBULIN IDIOTYPE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DENDRITIC CELL; HUMAN; HUMAN CELL; LYMPHOMA CELL; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANTIGEN PRESENTATION; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN IDIOTYPES; LYMPHOCYTE ACTIVATION; LYMPHOMA, FOLLICULAR; OPSONIN PROTEINS; PHAGOCYTOSIS; T-LYMPHOCYTE SUBSETS; TUMOR STEM CELLS;

EID: 0036843736     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200211000-00002     Document Type: Article

References (45)

1. Levy R, Hatzubia A, Brown S, et al. Immunoglobulin idiotype: A tumor-specific antigen for human B-cell lymphomas. In: Malignant Lymphomas, chapter 5, Academic Press 1982.
2. Roitt I, Brostoff J, Male D. Immunology, Second Ed. St. Louis: CV Mosby; 1989.
3. Miller RA, Maloney DG, Warnke R, et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-22.
4. Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal antiidiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992;80:1502-10.
5. Davis TA, Maloney DG, Czerwinski DK, et al. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998;92:1184-90.
6. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129-35.
7. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
8. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
9. Restifo NP, Wunderlich JR. Biology of cellular immune responses. In: DeVita VT, Hellman S, Rosenberg SA, Eds. Biologic Therapy of Cancer, 2nd ed. Philadelphia: J.B. Lippincott; 1995:3-37.
10. Rodriguez A, Regnault A, Kleijmeer M, et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1:362-8.
11. Carbone FR, Kurts C, Bennett SR, et al. Cross-presentation: A general mechanism for CTL immunity and tolerance. Immunol Today 1998;19:368-73.
12. Heath WR, Carbone FR. Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 1999;11:314-8.
13. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-9.
14. Castellino F, Boucher PE, Eichelberg K, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000;191:1957-64.
15. Singh-Jasuja H, Toes RE, Spee P, et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000;191:1965-74.
16. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999;189:371-80.
17. Machy P, Serre K, Leserman L. Class I-restricted presentation of exogenous antigen acquired by Fcgamma receptor-mediated endocytosis is regulated in dendritic cells. Eur J Immunol 2000;30:848-57.
18. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
19. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 2001;97:1750-5.
20. Chambers CA, Allison JP. Co-stimulation in T cell responses. Curr Opin Immunol 1997;9:396-404.
21. Chambers CA, Allison JP. Costimulatory regulation of T cell function. Curr Opin Cell Biol 1999;11:203-10.
22. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-47.
23. Chambers CA, Cado D, Truong T, et al. Thymocyte development is normal in CTLA-4-deficient mice. Proc Natl Acad Sci U S A 1997;94:9296-301.
24. Allison JP, Krummel MF. The yin and yang of T cell costimulation. Science 1995;270:932-33.
25. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
26. Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-7.
27. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.
28. Carroll WL, Thielemans K, Dilley J, et al. Mouse x human heterohybridomas as fusion partners with human B cell tumors. J Immunol Methods 1986;89:61-72.
29. Altin JG, Pagler EB. A one-step procedure for biotinylation and chemical cross-linking of lymphocyte surface and intracellular membrane-associated molecules. Anal Biochem 1995;224:382-9.
30. Clay TM, Hobeika AC, Mosca PJ, et al. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35.
31. + T cell cross-priming with exogenous antigens. J Immunol 2001;166:7268-75.
32. Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94.
33. Ferlazzo G, Semino C, Spaggiari GM, et al. Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol 2000;12:1741-7.
34. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999;163:130-6.
35. + T cells engaging class II molecules in cholesterol-rich domains. J Immunol 2002;168:1172-80.
36. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000;204:55-63.
37. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001;12:S1-4.
38. + cytotoxic T cells. Leukemia 2001;15:1619-26.
39. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000;60:2444-8.
40. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999;96:15074-9.
41. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999;190:355-66.
42. Hurwitz AA, Yu TF, Leach DR, et al. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998;95:10067-71.
43. Sotomayor EM, Borrello I, Tubb E, et al. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 1999;96:11476-81.
44. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
45. Gabrilovich DI, Nadaf S, Corak J, et al. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996;170:111-9.